Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
01 juil. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
25 juin 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
10 juin 2024 07h00 HE
|
Skye Bioscience, Inc.
SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile; program discontinued Phase 2 study of Nimacimab in obesity expected to start in Q3 2024 Cash runway extended into...
Skye Bioscience to Present at Jefferies Global Healthcare Conference
03 juin 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
10 mai 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel...
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
30 avr. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience to Present at Upcoming Investment Conferences
23 avr. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Uplists to The Nasdaq Global Market
10 avr. 2024 08h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
04 mars 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
26 févr. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and...